Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. Additionally, combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated potential benefits for patients with psoriasis and obesity, including improved immunometabolic health. The data reinforce Lilly's commitment to advancing treatments for chronic skin and metabolic conditions, with ongoing studies in pediatric populations and real-world settings. These findings could influence future treatment protocols and patient outcomes in dermatology and obesity management.
Eli Lilly's stock is trading at USD 1,140.80 on Pluang, showing a slight decline of 0.18% as of Oct 05, 2026 19:02 WIB. The company holds a strong market cap of $1.02 trillion, reflecting its significant presence in the health sector.
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, sugge...
Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also s...
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues....
